Skip to main content
AFK Sistema logo

AFK Sistema — Investor Relations & Filings

Ticker · AFKS ISIN · US48122U1051 LEI · 213800JSZ2UUK4QQK694 MOEX Administrative and support service activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2019-06-17 Capital/Financing Update
Country RU Russian Federation
Listing MOEX AFKS

About AFK Sistema

https://sistema.com/

AFK Sistema is a large, publicly-traded diversified holding company and a major private investor. The corporation manages a portfolio of assets across a wide range of sectors, including telecommunications, healthcare, agriculture, forestry, and fisheries. The company focuses on the strategic development and operational efficiency of its portfolio companies. A key element of its strategy is the implementation of digital solutions and advanced technologies to drive growth and innovation, with a notable emphasis on digital agrotech and the digitalization of healthcare services to improve quality and accessibility.

Recent filings

Filing Released Lang Actions
Sistema PJSFC: Sistema attracts unsecured loan from VTB Bank (PJSC)
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a new credit facility (loan) obtained by Sistema PJSFC from VTB Bank. It details the amount of the credit limit (RUB 17 billion) and the drawdown amount (RUB 6 billion) for debt refinancing. This falls under the category of company financing and capital structure updates.
2019-06-17 English
Sistema PJSFC: Sistema to acquire pharmaceutical companies Sintez and Biocom from Marathon Group
M&A Activity Classification · 100% confidence The document is an official announcement regarding a binding agreement for Sistema PJSFC to acquire pharmaceutical companies Sintez and Biocom from Marathon Group. This is a clear announcement of a merger and acquisition transaction. According to the filing definitions, documents related to merger proposals or takeover bids are classified as M&A Activity (TAR).
2019-06-07 English
SISTEMA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019
Earnings Release Classification · 100% confidence The document is a detailed financial results announcement for Sistema PJSFC for the first quarter of 2019. It includes consolidated financial highlights, management commentary, operational reviews of subsidiaries (MTS, Detsky Mir), and conference call details. While it contains financial data, it is the initial announcement of quarterly results rather than a full interim report or a standalone audit. Therefore, it is classified as an Earnings Release. Q1 2019
2019-06-04 English
Sistema PJSFC: Information on a transaction under the MTS share buyback programme
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding a share buyback transaction by a subsidiary of Sistema PJSFC. It details the sale of shares as part of an existing buyback program. Since the document reports on the company's own shares (or shares of a subsidiary in a buyback context) and is a specific transaction announcement, it falls under the category of 'Transaction in Own Shares'.
2019-05-06 English
Sistema PJSFC: Correction: Sistema and VTB to create a major pharmaceuticals holding
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement regarding a correction to a previous press release about a pharmaceutical merger/acquisition involving Sistema PJSFC and VTB. It details the acquisition of a stake in OBL Pharm and the subsequent merger with Binnopharm. Since this document describes M&A activity (merger and acquisition of a pharmaceutical holding), it falls under the M&A Activity category.
2019-04-26 English
Sistema PJSFC: RDIF, RCIF and Middle Eastern investors to acquire stake in OBL Pharm
Regulatory Filings Classification · 98% confidence The document is a press release announcing a corporate transaction where a consortium of investors (RDIF, RCIF, and others) is acquiring a stake in OBL Pharm, a company associated with Sistema PJSFC. This is a strategic business announcement regarding an investment and partnership, which falls under the category of M&A Activity (TAR) as it details the acquisition of equity and the consolidation of pharmaceutical assets.
2019-04-26 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.